Skip to main content

Esophageal Diseases

3
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
2
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Temple Therapeutics
Temple TherapeuticsNetherlands - Geleen
1 program
1
DronabinolPhase 41 trial
Active Trials
NCT02569073Withdrawn0Est. Sep 2019
Edwards Lifesciences
1 program
1
Vigileo MonitorPhase 41 trial
Active Trials
NCT00526331Completed49Est. Sep 2008
Harvard Apparatus Regenerative Technology
1 program
1
CEI Thoracic Surgical Implantation-Cellspan™ Esophageal Implant-AdultPhase 11 trial
Active Trials
NCT05877300Recruiting10Est. Dec 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Temple TherapeuticsDronabinol
Edwards LifesciencesVigileo Monitor
Harvard Apparatus Regenerative TechnologyCEI Thoracic Surgical Implantation-Cellspan™ Esophageal Implant-Adult

Clinical Trials (3)

Total enrollment: 59 patients across 3 trials

NCT02569073Temple TherapeuticsDronabinol

Investigation of Cannabinoid Receptor Agonist Dronabinol in Patients With Functional Chest Pain

Start: Jun 2017Est. completion: Sep 20190
Phase 4Withdrawn
NCT00526331Edwards LifesciencesVigileo Monitor

Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy

Start: Aug 2007Est. completion: Sep 200849 patients
Phase 4Completed
NCT05877300Harvard Apparatus Regenerative TechnologyCEI Thoracic Surgical Implantation-Cellspan™ Esophageal Implant-Adult

Safety and Feasibility Study of the CELLSPAN Esophageal Implant (CEI) in Patients Requiring Short Segment Esophageal Replacement

Start: Jul 2023Est. completion: Dec 202610 patients
Phase 1Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 59 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.